Pentagon Eyes Search for Virus-Fighting Protein ‘Cocktails’

Diane Barnes
Add to Briefcase
See more stories about...
Diane Barnes
Oct. 4, 2013, 10:02 a.m.

WASH­ING­TON — The U.S. De­fense De­part­ment is weigh­ing a new search for im­mune-pro­tein “cock­tails” it hopes will pro­tect hu­mans against Ebola and oth­er deadly, weapon-us­able vir­uses.

The Pentagon two weeks ago in­vited sci­ent­ists to sub­mit re­search pro­pos­als for design­ing “mono­clonal an­ti­bod­ies” that could pro­tect against Ebola and Mar­burg, as well as “al­phavir­uses” such as Venezuelan equine en­ceph­al­it­is.

Pentagon plan­ners have been turn­ing to an­ti­bod­ies as a pos­sible tool be­cause “no easy and quick fix” for such agents has emerged from ef­forts to de­vel­op vac­cines or tra­di­tion­al an­ti­vir­al treat­ments, said Gigi Gron­vall, a seni­or as­so­ci­ate with the Cen­ter for Health Se­cur­ity at the Uni­versity of Pitt­s­burgh Med­ic­al Cen­ter.

The early-stage re­search now un­der con­sid­er­a­tion ideally would lead to single-shot treat­ments cap­able of guard­ing troops for months from mul­tiple vir­us types, the De­fense Threat Re­duc­tion Agency said in a Sept. 18 so­li­cit­a­tion. DTRA of­fi­cials wel­comed re­search­ers to pro­pose “‘cock­tails’ that may en­able cross-pro­tec­tion against mul­tiple spe­cies of vir­us.”

The em­phas­is on “cock­tails” makes the latest DTRA pro­pos­al par­tic­u­larly not­able, be­cause sev­er­al stud­ies sug­gest that mixes of sev­er­al an­ti­bod­ies can be par­tic­u­larly ef­fect­ive in fight­ing patho­gens, Gron­vall told Glob­al Se­cur­ity News­wire in a tele­phone in­ter­view. An­ti­bod­ies hit their tar­gets with such spe­cificity that a treat­ment with mul­tiple im­mune pro­teins can help ac­count for slight vari­ations between in­vad­ing mi­crobes.

Mono­clonal an­ti­bod­ies have been in use since the 1980s to treat can­cer and im­mune-linked ail­ments such as rheum­at­oid arth­rit­is, but their use against in­fec­tious patho­gens has lagged, ac­cord­ing to a DTRA-sponsored re­port co-au­thored by Gron­vall on the tech­no­logy’s biode­fense po­ten­tial.

The United States last year li­censed the first in­hal­a­tion an­thrax treat­ment to use the tech­no­logy, which in­volves cre­at­ing massive quant­it­ies of a single im­mune “an­ti­body.” The hu­man body nat­ur­ally gen­er­ates such pro­teins, each of which is de­signed to mark a spe­cif­ic patho­gen or tox­in for elim­in­a­tion by oth­er im­mune-sys­tem com­pon­ents.

One an­ti­body cock­tail grown in mod­i­fied to­bacco plants showed prom­ising po­tency against Ebola in­fec­tions spe­cific­ally, ac­cord­ing to a study pub­lished in Au­gust.

“There have been a lot of changes in the way that mono­clonal an­ti­body tech­no­lo­gies have evolved over the last sev­er­al years, and it makes mono­clonal an­ti­bod­ies a very nice piece of their ap­proach to med­ic­al coun­ter­meas­ures,”  Gron­vall said.

The latest DTRA Broad Agency An­nounce­ment seeks pro­pos­als for stud­ies no longer than one year, with a cost no great­er than $500 mil­lion. The fil­ing dead­line is Oct. 16.

What We're Following See More »
CITES CONFLICT OF INTEREST
Lieberman Withdraws from Consideration for FBI Job
4 days ago
THE LATEST
MINIMUM 2 PERCENT GDP
Trump Tells NATO Countries To Pay Up
4 days ago
BREAKING
MANAFORT AND FLYNN
Russians Discussed Influencing Trump Through Aides
4 days ago
THE DETAILS

"American spies collected information last summer revealing that senior Russian intelligence and political officials were discussing how to exert influence over Donald J. Trump through his advisers." The conversations centered around Paul Manafort, who was campaign chairman at the time, and Michael Flynn, former national security adviser and then a close campaign surrogate. Both men have been tied heavily with Russia and Flynn is currently at the center of the FBI investigation into possible collusion between the Trump campaign and Russia.

Source:
BUT WHITE HOUSE MAY USE AGAINST HIM ANYWAY
Ethics Cops Clear Mueller to Work on Trump Case
6 days ago
THE LATEST

"Former FBI Director Robert Mueller has been cleared by U.S. Department of Justice ethics experts to oversee an investigation into possible collusion between then-candidate Donald Trump's 2016 election campaign and Russia." Some had speculated that the White House would use "an ethics rule limiting government attorneys from investigating people their former law firm represented" to trip up Mueller's appointment. Jared Kushner is a client of Mueller's firm, WilmerHale. "Although Mueller has now been cleared by the Justice Department, the White House may still use his former law firm's connection to Manafort and Kushner to undermine the findings of his investigation, according to two sources close to the White House."

Source:
BUSINESSES CAN’T PLEAD FIFTH
Senate Intel to Subpoena Two of Flynn’s Businesses
6 days ago
THE LATEST

Senate Intelligence Committee chairman Richard Burr (R-NC) and ranking member Mark Warner (D-VA) will subpoena two businesses owned by former National Security Advisor Michael Flynn. Burr said, "We would like to hear from General Flynn. We'd like to see his documents. We'd like him to tell his story because he publicly said he had a story to tell."

×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login